GAO re­port rais­es ques­tions about reau­tho­riz­ing two PRV pro­grams

With the rare pe­di­atric dis­ease and med­ical coun­ter­mea­sure pri­or­i­ty re­view vouch­er (PRV) pro­grams set to ex­pire by 2022 and 2023, re­spec­tive­ly, the Gov­ern­ment Ac­count­abil­i­ty Of­fice (GAO) re­leased a new re­port Fri­day on the suc­cess­es and hic­cups in all three PRV pro­grams and what stake­hold­ers think.

The PRV pro­grams in­cen­tivize com­pa­nies to de­vel­op new rare pe­di­atric dis­ease, trop­i­cal dis­ease and med­ical coun­ter­mea­sure drugs by pro­vid­ing the com­pa­nies with a vouch­er when a new treat­ment is ap­proved. The vouch­er can be used to speed the re­view of an­oth­er drug or sold to an­oth­er com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER